Bendamustine/polatuzumab-vedotin/rituximab: Cytokine release syndrome.

A retrospective analysis of 25 patients with large B-cell lymphoma (LBCL) found that one patient developed cytokine release syndrome (CRS) during treatment with polatuzumab-vedotin, bendamustine, and rituximab. The patient underwent leukapheresis and received bridging chemotherapy with the aforementioned drugs. However, they experienced grade 3 or worse CRS as a result of the treatment. The specific details regarding dosages, routes, durations of treatments, and the patient's outcome were not provided. [Extracted from the article]